Welcome
Support Centre
12 February 2012 
Current Controlled Trials - Clinical Trials
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Introduction
English introduction Introduction en français Deutsche einleitung
Introducción española Introduzione in italiano
 
Find trials
active registers
mental health register
archived registers
all registers
tips on searching
 
 
Information
about mRCT
mRCT FAQs

DISCLAIMER
The site should not be used to diagnose or treat a health problem. Please consult your doctor.
Terms & conditions

DUPLICATION
Your search result may contain a number of different records for the same trial. This occurs when the same trial is listed in more than one register.

[ ...Back to search results ] [ Print-friendly version ]
The Middlesbrough study: a randomised, controlled trial of dietary supplements with omega-3/omega-6 fatty acids in mainstream school children
Source of recordUK Trials
ISRCTNISRCTN12286781
Date ISRCTN assigned28/09/2007
Local reference number(s)DCC-RCT-MIDD-00001
Public titleThe Middlesbrough study: a randomised, controlled trial of dietary supplements with omega-3/omega-6 fatty acids in mainstream school children
Scientific title
AcronymN/A
Disease/condition/study domainPoor concentration, hyperactivity, learning abilities and working memory
Study hypothesisOmega-3 consumption in children in western Countries has been declining. At the same time there has been concerns about the increased levels of poor concentration, hyperactivity and learning difficulties evidenced in the UK school population. Of these children a proportion (30%) do not appear to respond to standard interventions and a large proportion were found to have eczema, asthma, lactose intolerance and other allergies that may be related to dietary deficiencies. The focus of this study is to determine the effect of dietary intervention on learning and behavioural conditions.

Previous Randomised Controlled Trials (RCTs) have indicated a positive effect on reducing hyperactivity and improved educational attainment in children with specific learning difficulties (Dyslexia/Developmental Coordination Disorder [Dyspraxia] and Attention Deficit Hyperactivity Disorder [ADHD]) following dietary supplementation with omega-3/omega-6 fatty acids. This trial will test the hypothesis that similar effects are evident with dietary omega-3/omega-6 supplementation in a cross-section of mainstream schoolchildren, who do not have diagnosed learning difficulties/behavioural problems.
Design/methodologyInterventional, multi-centre, randomised double-blind, placebo controlled, one-way crossover study
Research ethics reviewApproval was sought in March 2005 from South Tees Local Research Ethics Committee. At that time, the committee stated "This study does not fall within Section 3 of Governance Arrangements for Research Ethics Committees (GAfREC), which identifies that ethical advice from the appropriate NHS REC is required for any research involving activities within Section 3.1 a-g".

The committee were asked to review their decision and their response has been:

"In accordance with Section 1.88 of the Standard Operating Procedures for Research Ethics Committees (SOPs), I have been asked to review the file and to comment. I have been asked for my opinion as Chair of County Durham and Tees Valley 1 REC. I was Chair of South Tees LREC in April 2005.

"If submitted for full review by the LREC, it must be judged by the standard and requirements at the time, that is Spring 2005. This project is an extension of previous work, but in this case specifically looking to recruit a different child population, including children that were educationally underachieving.

"The research team and facilities were appropriate. The only identified risk was a minimal risk of mild digestive upset with a reported rate of 3%. Standard psychometric assessments were proposed. Children were randomly allocated to the active or a placebo supplement and the researchers were 'blinded' to the allocation.

"The welfare of all the participants was appropriately safeguarded and the exclusion criteria sensible.

"The provision of information to the school staff, general practitioners, parents and children were satisfactory and consent dealt with appropriately. In my view, the Committee at that time would have given a 'favourable' opinion."
Countries of trialUnited Kingdom
Participants - inclusion criteriaParticipants attend mainstream school.
Participants - exclusion criteriaChildren with:
1. Significant neurological problems
2. Psychiatric conditions
3. Any of the following medical problems:
3.1. Epilepsy
3.2. Cerebral palsy
3.3. Multiple sclerosis
3.4. Myalgic encephalopathy
3.5. Pervasive developmental disorder
3.6. Autism
4. Diagnosed ADHD
5. Consumption of essential fatty-acid supplementation within previous three months
Patient information material
Anticipated start date01/04/2005
Anticipated end date31/01/2006
Status of trialCompleted
Target number of participants250
InterventionsActive treatment: dietary supplement (Eye q):
Omega-3/omega-6 dietary supplement in capsule form, six times/day providing 558 mg Eicosapentaenoic Acid (EPA), 174 mg Docosahexaenoic Acid (DHA), 60 mg Gamma Linolenic Acid for duration of trial.

Control group: dietary supplement (placebo):
Placebo containing medium-chain triglycerides derived from olive oil, 4% of the capsule comprised EPA and DHA to ensure a fishy taste and carrot oil macerate for colouring. After three months this group crossed over to the active treatment.

The duration of the treatment was six months (one-way crossover from placebo to active after three months) with staggered entry over two months. Assessments for primary/secondary outcome measures were completed at baseline, three and six months. A random sample of 50 participants will be tracked until they leave school, aged 16/18. Follow up will involve monitoring participants' attainments in National Tests (KS 1, 2 and 3 results and performance at KS4 via GCSE/Vocational qualifications).
Primary outcome measure(s)1. Measurement of change in working memory, confirmed by results from Wechsler Intelligence Scale for Children (WISC-III UK) digit span assessment; time frame: 6 months
2. Measurement of change in reading ability, using the Wechsler Objective Reading Dimensions (WORD) assessment; time frame: 6 months
Secondary outcome measure(s)1. Measuring a range of behavioural parameters including cognitive problems, hyperactivity, social problems, ADHD and emotional lability as identified by parents using the Conners' Parent Rating Scales-Long Version (CPRS-L); time frame: 6 months
2. Measuring a range of behavioural parameters including cognitive problems, hyperactivity, social problems, ADHD and emotional lability as identified by teachers using the Conners' Teacher Rating Scales-Long Version (CTRS-L); time frame: 6 months
Sources of funding1. Middlesbrough Council (UK) - funding
2. Durham County Council (UK) - funding
3. Equazen Ltd (UK) - provided active and placebo treatments
Sponsor nameDurham County Council (UK)
Sponsor detailsCounty Hall
Durham
United Kingdom
DH1 5UJ
Sponsor telephone+44 (0)191 383 000
Sponsor emailmadeleine.portwood@durham.gov.uk
Sponsor websitehttp://www.durham.gov.uk/
Contact nameDr Madeleine Portwood
Contact detailsEducation Development Centre
Enterprise Way
Spennymoore
United Kingdom
DL16 6JE
Contact telephone+44 (0)1388 424 901
Contact emailmadeleine.portwood@durham.gov.uk
More informationFor more up-to-date information please go to the ISRCTN link below.
Link to record in ISRCTN RegisterISRCTN12286781
Date last extracted from ISRCTN register17/04/2008
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 Current Controlled Trials Ltd. Part of Springer Science+Business Media. | terms & conditions | privacy statement


BioMed Central